Avalo director granted options on 1,080 shares

Avalo Therapeutics director Rita Jain received a stock option grant as part of her compensation.

Rhea-AI Filing Summary

Avalo Therapeutics director Rita Jain received a stock option grant as part of her compensation. On June 30, 2026, she was awarded options covering 1,080 shares of Avalo Therapeutics common stock at an exercise price of $18.48 per share. These options are fully vested and expire on June 30, 2036. Following this grant, she directly holds options on 1,080 underlying shares.

Insider Trade Summary

Grant/Award: 1,080 shares

Grant/Award 1 txn

Insider Jain Rita

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	1,080	$15.04	$16K

Holdings After Transaction: Stock Option (Right to Buy) — 1,080 contracts (Direct)

Footnotes (1)

1. F1. The options were granted on June 30, 2026, and are 100% vested.

Key Figures

Options granted: 1,080 shares Exercise price: $18.48 per share Transaction value reference: $15.04 per option +2 more

5 metrics

Options granted 1,080 shares Stock options granted on June 30, 2026

Exercise price $18.48 per share Conversion or exercise price of stock options

Transaction value reference $15.04 per option Reported transaction price per option share

Options after transaction 1,080 shares Total underlying shares following grant

Option expiration June 30, 2036 Expiration date of the stock options

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, Common Stock, Exercise price

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Common Stock financial

"underlying_security_title: Common Stock"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Exercise price financial

"conversion_or_exercise_price: 18.4800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Avalo Therapeutics (AVTX) director Rita Jain report in this Form 4?

Rita Jain reported receiving a stock option grant for 1,080 shares of Avalo Therapeutics common stock. The options were granted as compensation, are fully vested on the grant date, and give her the right to buy shares at a fixed exercise price.

How many Avalo Therapeutics (AVTX) shares are covered by Rita Jain’s new options?

The new stock option grant covers 1,080 underlying shares of Avalo Therapeutics common stock. This means she can purchase up to 1,080 shares at the specified exercise price if she chooses to exercise the options before they expire.

What is the exercise price of Rita Jain’s Avalo Therapeutics (AVTX) stock options?

The exercise price of the options is $18.48 per share. This is the fixed price at which she can buy Avalo Therapeutics common stock through these options, regardless of the market price at the time of exercise, until the options expire.

When do Rita Jain’s Avalo Therapeutics (AVTX) stock options vest and expire?

The options were granted on June 30, 2026 and are 100% vested immediately. They have an expiration date of June 30, 2036, giving a ten-year window during which she may choose to exercise the options for Avalo Therapeutics shares.

How many Avalo Therapeutics (AVTX) options does Rita Jain hold after this transaction?

After this grant, Rita Jain directly holds stock options covering 1,080 underlying shares of Avalo Therapeutics common stock. The Form 4 shows this total as her option holdings following the reported transaction on June 30, 2026.

Is Rita Jain’s Form 4 for Avalo Therapeutics (AVTX) a market purchase or sale?

The Form 4 reports a grant of stock options, not a market purchase or sale. The transaction code is “A” for a grant, award, or other acquisition, meaning she received options as compensation rather than buying or selling shares in the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/02/2026 - 04:05 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jain Rita

(Last) (First) (Middle)

C/O AVALO THERAPEUTICS, INC.

1500 LIBERTY RIDGE DRIVE, SUITE 321

(Street)

WAYNE PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Avalo Therapeutics, Inc. [ AVTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$18.48	06/30/2026		A		1,080		(1)	06/30/2036	Common Stock	1,080	$15.04	1,080	D

Explanation of Responses:

1. The options were granted on June 30, 2026, and are 100% vested.

	/s/ Christopher Sullivan, Attorney-in-Fact	07/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)